Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5359677 | 0.98 | MAPT (0.35) | NPSR1MAPTDGAT1ALDH1A1L3MBTL1 | |
| SCHEMBL28067161 | 0.92 | DGAT1 (0.34) | DGAT1CYP4F2CYP4A11 | |
| SCHEMBL4734782 | 0.79 | MAPT (0.47) | NPSR1MAPTALDH1A1L3MBTL1CYP4F2 | |
| SCHEMBL15461474 | 0.79 | NPSR1 (0.32) | NPSR1MAPTDGAT1ALDH1A1L3MBTL1 | |
| SCHEMBL15461486 | 0.78 | MAPT (0.34) | NPSR1MAPTDGAT1ALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL25233263 | 0.76 | MAPT (0.49) | NPSR1MAPTALDH1A1L3MBTL1CYP4F2 | |
| SCHEMBL6864504 | 0.75 | MME (0.33) | NPSR1CYP4F2CYP4A11 | |
| SCHEMBL1782571 | 0.74 | MME (0.33) | MAPTALDH1A1L3MBTL1 | |
| SCHEMBL3295142 | 0.74 | MAPK1 (0.33) | NPSR1DGAT1CYP4F2CYP4A11 | |
| SCHEMBL740941 | 0.74 | NPSR1 (0.32) | NPSR1DGAT1CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241763-B2 | 3-furanyl analogs of toxoflavine as kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | disclosed |
| EP-1523485-B1 | 3-FURANYL ANALOGS OF TOXOFLAVINE AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-14 | — | — | EP | disclosed |
| US-20060040943-A1 | 3-Furanyl analogs of toxoflavine as kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-23 | — | — | US | disclosed |
| EP-1523485-A1 | 3-FURANYL ANALOGS OF TOXOFLAVINE AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-04-20 | — | — | EP | disclosed |
| WO-2004007499-A1 | 3-FURANYL ANALOGS OF TOXOFLAVINE AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040943-A1 | 3-Furanyl analogs of toxoflavine as kinase inhibitors | GRK3, GRK4, GRK6 | NPSR1 421/4885MAPT 4881/4885DGAT1 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.